The SPLIT research agenda 2013

Pediatric Transplantation

Volumn 17, Issue 5, 2013, Pages 412-422

  Alonso, Estella M ^a   Ng, Vicky L ^b   Anand, Ravinder ^c   Anderson, Christopher D ^d   Ekong, Udeme D ^a   Fredericks, Emily M ^e   Furuya, Katryn N ^f   Gupta, Nitika A ^g   Lerret, Stacee M ^h   Sundaram, Shikha ⁱ   Tiao, Greg ^j  

^a CHILDREN'S MEMORIAL HOSPITAL   (United States)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

^c EMMES CORPORATION   (United States)

^d UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

^e UNIVERSITY OF MICHIGAN   (United States)

^f THOMAS JEFFERSON UNIVERSITY   (United States)

^g EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h MEDICAL COLLEGE OF WISCONSIN   (United States)

ⁱ University of Colorado Denver and Children s Hospital Colorado   (United States)

^j CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

more..

Author keywords

health outcomes; indications; long term results; outcome; pediatric liver transplantation

Indexed keywords

ANTICOAGULANT AGENT; ANTINEOPLASTIC AGENT; IMMUNOSUPPRESSIVE AGENT;

CANCER ADJUVANT THERAPY; CHOLESTASIS; CLINICAL PROTOCOL; DRUG WITHDRAWAL; HEPATOBLASTOMA; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; LIVER CELL CARCINOMA; LIVER FUNCTION; LIVER GRAFT REJECTION; LIVER LOBECTOMY; LIVER TRANSPLANTATION; LONGITUDINAL STUDY; MEDICAL RESEARCH; MODEL FOR END STAGE LIVER DISEASE SCORE; OBSERVATIONAL STUDY; ORGAN DONOR; PEDIATRIC SURGERY; POSTOPERATIVE COMPLICATION; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; SURVIVAL TIME; SURVIVOR; TREATMENT INDICATION; TREATMENT PLANNING;

HEALTH OUTCOMES; INDICATIONS; LONG-TERM RESULTS; OUTCOME; PEDIATRIC LIVER TRANSPLANTATION;

BIOMEDICAL RESEARCH; CARCINOMA, HEPATOCELLULAR; CHILD; GRAFT SURVIVAL; HEPATOBLASTOMA; HUMANS; IMMUNE TOLERANCE; LIVER FAILURE; LIVER NEOPLASMS; LIVER TRANSPLANTATION; PATIENT COMPLIANCE; PEDIATRICS; SOCIETIES, MEDICAL; TREATMENT OUTCOME;

EID: 84879856272     PISSN: 13973142     EISSN: 13993046     Source Type: Journal    
DOI: 10.1111/petr.12090     Document Type: Review

References (77)

1. Feng S, Goodrich NP, Bragg-Gresham JL, et al. Characteristics associated with liver graft failure: The concept of a donor risk index. Am J Transplant 2006: 6: 783-790.
2. Schaubel DE, Sima CS, Goodrich NP, Feng S, Merion RM,. The survival benefit of deceased donor liver transplantation as a function of candidate disease severity and donor quality. Am J Transplant 2008: 8: 419-425.
3. Anderson CD, Turmelle YP, Lowell JA, et al. The effect of recipient-specific surgical issues on outcome of liver transplantation in biliary atresia. Am J Transplant 2008: 8: 1197-1204.
4. Diamond IR, Fecteau A, Millis JM, et al. Impact of graft type on outcome in pediatric liver transplantation: A report From Studies of Pediatric Liver Transplantation (SPLIT). Ann Surg 2007: 246: 301-310.
5. Cacciarelli TV, Dvorchik I, Mazariegos GV, et al. An analysis of pretransplantation variables associated with long-term allograft outcome in pediatric liver transplant recipients receiving primary tacrolimus (FK506) therapy. Transplantation 1999: 68: 650-655.
6. Anderson CD, Turmelle YP, Darcy M, et al. Biliary strictures in pediatric liver transplant recipients-early diagnosis and treatment results in excellent graft outcomes. Pediatr Transplant 2010: 14: 358-363.
7. McLaughlin CC, Baptiste MS, Schymura MJ, Nasca PC, Zdeb MS,. Maternal and infant birth characteristics and hepatoblastoma. Am J Epidemiol 2006: 163: 818-828.
8. Bulterys M, Goodman M, Smith M, Jd B,. Hepatic tumors. In:, Ries LAG, Smith MA, Gurney JG, et al., eds. Cancer Incidence and Survival among Children and Adolescents: United States SEER Program 1975-1995. Bethesda, MD: National Cancer Institute, 1999.
9. Plaschkes J, Perilongo G, Shafford E, et al. SIOP trial report-overall preliminary results of SIOPEL-1 for the treatment of hepatoblastoma (HB) with pre-operative chemotherapy-continuous infusion cisplatin and doxorubicin (PLADO). 1994.
10. Roebuck DJ, Aronson D, Clapuyt P, et al. 2005 PRETEXT: A revised staging system for primary malignant liver tumours of childhood developed by the SIOPEL group. Pediatr Radiol 2007: 37: 123-132; quiz 249-150.
11. Superina R, Bilik R,. Results of liver transplantation in children with unresectable liver tumors. J Pediatr Surg 1996: 31: 835-839.
12. Reyes JD, Carr B, Dvorchik I, et al. Liver transplantation and chemotherapy for hepatoblastoma and hepatocellular cancer in childhood and adolescence. J Pediatr 2000: 136: 795-804.
13. Al-Qabandi W, Jenkinson HC, Buckels JA, et al. Orthotopic liver transplantation for unresectable hepatoblastoma: A single center's experience. J Pediatr Surg 1999: 34: 1261-1264.
14. Zsiros J, Maibach R, Shafford E, et al. Successful treatment of childhood high-risk hepatoblastoma with dose-intensive multiagent chemotherapy and surgery: Final results of the SIOPEL-3HR study. J Clin Oncol 2010: 28: 2584-2590.
15. Otte JB, Pritchard J, Aronson DC, et al. Liver transplantation for hepatoblastoma: Results from the International Society of Pediatric Oncology (SIOP) study SIOPEL-1 and review of the world experience. Pediatr Blood Cancer 2004: 42: 74-83.
16. Pimpalwar AP, Sharif K, Ramani P, et al. Strategy for hepatoblastoma management: Transplant versus nontransplant surgery. J Pediatr Surg 2002: 37: 240-245.
17. Avila L, Encinas J, Leal N, et al. Liver transplantation for malignant tumors in children. Cir Pediatr 2007: 20: 189-193.
18. Casas-Melley A, Malatack J, Consolini DJ, et al. Successful liver transplant for unresectable hepatoblastoma. J Pediatr Surg 2007: 42: 184-187.
19. Browne M, Sher D, Grant D, et al. Survival after liver transplantation for hepatoblastoma: A 2-center experience. J Pediatr Surg 2008: 43: 1973-1981.
20. Otte JB,. Progress in the surgical treatment of malignant liver tumors in children. Cancer Treat Rev 2010: 36: 360-371.
21. Malogolowkin MH, Katzenstein H, Krailo MD, et al. Intensified platinum therapy is an ineffective strategy for improving outcome in pediatric patients with advanced hepatoblastoma. J Clin Oncol 2006: 24: 2879-2884.
22. Warmann S, Fuchs J,. Drug resistance in hepatoblastoma. Curr Pharm Biotechnol 2007: 8: 93-97.
23. Otte JB, Meyers R,. PLUTO first report. Pediatr Transplant 2010: 14: 830-835.
24. Darbari A, Sabin KM, Shapiro CN, Schwarz KB,. Epidemiology of primary hepatic malignancies in U.S. children. Hepatology 2003: 38: 560-566.
25. Zimmermann A,. Hepatoblastoma with cholangioblastic features ('cholangioblastic hepatoblastoma') and other liver tumors with bimodal differentiation in young patients. Med Pediatr Oncol 2002: 39: 487-491.
26. Zimmermann A,. The emerging family of hepatoblastoma tumours: From ontogenesis to oncogenesis. Eur J Cancer 2005: 41: 1503-1514.
27. Katzenstein HM, Krailo MD, Malogolowkin MH, et al. Hepatocellular carcinoma in children and adolescents: Results from the Pediatric Oncology Group and the Children's Cancer Group intergroup study. J Clin Oncol 2002: 20: 2789-2797.
28. Czauderna P, Mackinlay G, Perilongo G, et al. Hepatocellular carcinoma in children: Results of the first prospective study of the International Society of Pediatric Oncology group. J Clin Oncol 2002: 20: 2798-2804.
29. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996: 334: 693-699.
30. Prokurat A, Kluge P, Kosciesza A, Perek D, Kappeler A, Zimmermann A,. Transitional liver cell tumors (TLCT) in older children and adolescents: A novel group of aggressive hepatic tumors expressing beta-catenin. Med Pediatr Oncol 2002: 39: 510-518.
31. Beaunoyer M, Vanatta JM, Ogihara M, et al. Outcomes of transplantation in children with primary hepatic malignancy. Pediatr Transplant 2007: 11: 655-660.
32. Ismail H, Broniszczak D, Kalicinski P, et al. Liver transplantation in children with hepatocellular carcinoma. Do Milan criteria apply to pediatric patients? Pediatr Transplant 2009: 13: 682-692.
33. Gupta AA, Gerstle JT, Ng V, et al. Critical review of controversial issues in the management of advanced pediatric liver tumors. Pediatr Blood Cancer 2011: 56: 1013-1018.
34. Mazariegos GV, Sindhi R, Thomson AW, Marcos A,. Clinical tolerance following liver transplantation: Long term results and future prospects. Transpl Immunol 2007: 17: 114-119.
35. Koshiba T, Li Y, Takemura M, et al. Clinical, immunological, and pathological aspects of operational tolerance after pediatric living-donor liver transplantation. Transpl Immunol 2007: 17: 94-97.
36. Takatsuki M, Uemoto S, Inomata Y, et al. Weaning of immunosuppression in living donor liver transplant recipients. Transplantation 2001: 72: 449-454.
37. Feng S, Ekong UD, Lobritto SJ, et al. Complete immunosuppression withdrawal and subsequent allograft function among pediatric recipients of parental living donor liver transplants. JAMA 2012: 307: 283-293.
38. Ansari MJ, Sayegh MH,. Clinical transplantation tolerance: The promise and challenges. Kidney Int 2004: 65: 1560-1563.
39. Demetris AJ, Lunz JG III, Randhawa P, Wu T, Nalesnik M, Thomson AW,. Monitoring of human liver and kidney allograft tolerance: A tissue/ histopathology perspective. Transpl Int 2009: 22: 120-141.
40. Evans HM, Kelly DA, McKiernan PJ, Hubscher S,. Progressive histological damage in liver allografts following pediatric liver transplantation. Hepatology 2006: 43: 1109-1117.
41. Scheenstra R, Peeters PM, Verkade HJ, Gouw AS,. Graft fibrosis after pediatric liver transplantation: Ten years of follow-up. Hepatology 2009: 49: 880-886.
42. Abraham SC, Poterucha JJ, Rosen CB, Demetris AJ, Krasinskas AM,. Histologic abnormalities are common in protocol liver allograft biopsies from patients with normal liver function tests. Am J Surg Pathol 2008: 32: 965-973.
43. Ekong UD, Melin-Aldana H, Seshadri R, et al. Graft histology characteristics in long-term survivors of pediatric liver transplantation. Liver Transpl 2008: 14: 1582-1587.
44. Mells G, Mann C, Hubscher S, Neuberger J,. Late protocol liver biopsies in the liver allograft: A neglected investigation? Liver Transpl 2009: 15: 931-938.
45. Ng VL, Fecteau A, Shepherd R, et al. Outcomes of 5-year survivors of pediatric liver transplantation: Report on 461 children from a north american multicenter registry. Pediatrics 2008: 122: e1128-e1135.
46. Ng VL, Alonso EM, Bucuvalas JC, et al. Health status of children alive 10 years after pediatric liver transplantation performed in the US and Canada: Report of the studies of pediatric liver transplantation experience. J Pediatr 2012: 160: 820-826 e823.
47. Campbell K, Ng V, Martin S, et al. Glomerular filtration rate following pediatric liver transplantation-the SPLIT experience. Am J Transplant 2010: 10: 2673-2682.
48. Sundaram SS, Alonso EM, Zeitler P, Yin W, Anand R,. Obesity after pediatric liver transplantation: Prevalence and risk factors. J Pediatr Gastroenterol Nutr 2012 Jun 28: PMID: 22744193.
49. Liem RI, Anand R, Yin W, Alonso EM,. Risk factors for chronic anemia in pediatric orthotopic liver transplantation: Analysis of data from the SPLIT registry. Pediatr Transplant 2012: 16: 137-143.
50. McLin VA, Anand R, Daniels SR, Yin W, Alonso EM,. Blood pressure elevation in long-term survivors of pediatric liver transplantation. Am J Transplant 2012: 12: 183-190.
51. Hathout E, Alonso E, Anand R, et al. Post-transplant diabetes mellitus in pediatric liver transplantation. Pediatr Transplant 2009: 13: 599-605.
52. McDiarmid SV, Anand R, Martz K, Millis MJ, Mazariegos G,. A multivariate analysis of pre-, peri-, and post-transplant factors affecting outcome after pediatric liver transplantation. Ann Surg 2011: 254: 145-154.
53. La Greca AM, Bearman KJ,. Adherence to pediatric treatment regimens. In:, Roberts MC, ed. Handbook of Pediatric Psychology. New York: The Guilford Press, 2003: pp. 119-140.
54. Shaw R,. Treatment adherence in adolescents: Development and psychopathology. Clin Child Psychol Psychiatry 2001: 6: 137-150.
55. Suris JC, Michaud PA, Viner R,. The adolescent with a chronic condition. Part I: Developmental issues. Arch Dis Child 2004: 89: 938-942.
56. Dew MA, Dabbs AD, Myaskovsky L, et al. Meta-analysis of medical regimen adherence outcomes in pediatric solid organ transplantation. Transplantation 2009: 88: 736-746.
57. Dobbels F, Van Damme-Lombaert R, Vanhaecke J, De Geest S,. Growing pains: Non-adherence with the immunosuppressive regimen in adolescent transplant recipients. Pediatr Transplant 2005: 9: 381-390.
58. Kahana SY, Frazier TW, Drotar D,. Preliminary quantitative investigation of predictors of treatment non-adherence in pediatric transplantation: A brief report. Pediatr Transplant 2008: 12: 656-660.
59. Fredericks EM, Lopez MJ, Magee JC, Shieck V, Opipari-Arrigan L,. Psychological functioning, nonadherence and health outcomes after pediatric liver transplantation. Am J Transplant 2007: 7: 1974-1983.
60. Fredericks EM, Magee JC, Opipari-Arrigan L, Shieck V, Well A, Lopez MJ,. Adherence and health-related quality of life in adolescent liver transplant recipients. Pediatr Transplant 2008: 12: 289-299.
61. Griffin KJ, Elkin TD,. Non-adherence in pediatric transplantation: A review of the existing literature. Pediatr Transplant 2001: 5: 246-249.
62. Pinsky BW, Takemoto SK, Lentine KL, Burroughs TE, Schnitzler MA, Salvalaggio PR,. Transplant outcomes and economic costs associated with patient noncompliance to immunosuppression. Am J Transplant 2009: 9: 2597-2606.
63. Watson AR,. Non-compliance and transfer from paediatric to adult transplant unit. Pediatr Nephrol 2000: 14: 469-472.
64. Annunziato RA, Emre S, Shneider B, Barton C, Dugan CA, Shemesh E,. Adherence and medical outcomes in pediatric liver transplant recipients who transition to adult services. Pediatr Transplant 2007: 11: 608-614.
65. Fine RN, Becker Y, De Geest S, et al. Nonadherence consensus conference summary report. Am J Transplant 2009: 9: 35-41.
66. Bucuvalas JC, Ryckman FC, Arya G, et al. A novel approach to managing variation: Outpatient therapeutic monitoring of calcineurin inhibitor blood levels in liver transplant recipients. J Pediatr 2005: 146: 744-750.
67. Shemesh E, Shneider BL, Savitzky JK, et al. Medication adherence in pediatric and adolescent liver transplant recipients. Pediatrics 2004: 113: 825-832.
68. Stuber ML, Shemesh E, Seacord D, Washington J III, Hellemann G, McDiarmid S,. Evaluating non-adherence to immunosuppressant medications in pediatric liver transplant recipients. Pediatr Transplant 2008: 12: 284-288.
69. Blum RW, Garell D, Hodgman CH, et al. Transition from child-centered to adult health-care systems for adolescents with chronic conditions. A position paper of the Society for Adolescent Medicine. J Adolesc Health 1993: 14: 570-576.
70. Kennedy A, Sawyer S,. Transition from pediatric to adult services: Are we getting it right? Curr Opin Pediatr 2008: 20: 403-409.
71. Sawyer SM, Blair S, Bowes G,. Chronic illness in adolescents: Transfer or transition to adult services? J Paediatr Child Health 1997: 33: 88-90.
72. Kieckhefer GM, Trahms CM,. Supporting development of children with chronic conditions: From compliance toward shared management. Pediatr Nurs 2000: 26: 354-363.
73. Watson AR,. Problems and pitfalls of transition from paediatric to adult renal care. Pediatr Nephrol 2005: 20: 113-117.
74. Fredericks EM, Dore-Stites D, Well A, et al. Assessment of transition readiness skills and adherence in pediatric liver transplant recipients. Pediatr Transplant 2010: 14: 944-953.
75. McDonagh JE, Hackett J,. Interrelationship of self-management and transitional care needs of adolescents with arthritis: Comment on the article by Stinson et al. Arthritis Rheum 2008: 59: 1199-1200; author reply 1200-1191.
76. Viner R,. Transition from paediatric to adult care. Bridging the gaps or passing the buck? Arch Dis Child 1999: 81: 271-275.
77. McDonagh JE, Kelly DA,. Trans-plan-sition! Transplantation and transition. Pediatr Transplant 2007: 11: 578-581.